By Joshua Oyster, Beth Weinman and Helen Ryan ( January 19, 2022, 5:52 PM EST) -- In late December 2021, the U.S. Food and Drug Administration issued two draft guidance documents regarding unapproved medical devices that the FDA has allowed to be marketed during the COVID-19 pandemic: one details transition plans for devices issued emergency use authorizations, or EUAs, under Section 564 of the Federal Food Drug and Cosmetic Act;[1] the other addresses devices subject to the FDA's COVID-19-related enforcement policies.[2]...
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.